2021
503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial
Wermke M, Marabelle A, Jungels C, Bono J, Vey N, Vicier C, Garralda E, Gouill S, LoRusso P, Champiat S, List C, Aguiar V, Wetzko K, Rhunke L, Gassart A, Brune P, Valentin E, Iche M, Olive D, Frohna P. 503 Clinical activity of ICT01, an anti-BTN3A-targeted, γ9δ2-activating mAb, alone and in combination with pembrolizumab in patients with advanced/refractory solid tumors: EVICTION trial. 2021, a535-a535. DOI: 10.1136/jitc-2021-sitc2021.503.Peer-Reviewed Original ResearchΓ9δ2 T cellsCD8 T cellsRefractory solid tumorsSolid tumor patientsT cellsSolid tumorsTumor patientsBroad antitumor immune responseHospital Universitari Vall d’HebronEthics CommitteeT-cell countsAntitumor immune responseTumor-infiltrating lymphocytesNK cell activationPreliminary efficacy dataInstitut Jules BordetDose-dependent increaseSubsequent clinical benefitCytokine level analysisCommon AEsDose cohortsEudraCT numberLow TILsPhase 1/2aSerum cytokines
2020
A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab.
Patel M, Bauer T, Jimeno A, Wang D, LoRusso P, Do K, Stemmer S, Maurice-Dror C, Geva R, Zacharek S, Laino A, Sun J, Frederick J, Zhou H, Randolph W, Cohen P, Meehan R, Sullivan R. A phase I study of mRNA-2752, a lipid nanoparticle encapsulating mRNAs encoding human OX40L, IL-23, and IL-36γ, for intratumoral (iTu) injection alone and in combination with durvalumab. Journal Of Clinical Oncology 2020, 38: 3092-3092. DOI: 10.1200/jco.2020.38.15_suppl.3092.Peer-Reviewed Original ResearchSolid tumor patientsPro-inflammatory cytokinesIL-23IL-36γTumor shrinkageTumor patientsPost-treatment tumor biopsiesSquamous cell bladder carcinomaTumor-associated immune cellsDose-escalation partAdvanced solid malignanciesGrade 3/4 toxicitiesCytokine IL-22PD-L1 expressionPD-L1 levelsPD-L1 immunohistochemistryTime of presentationAnalysis of tumorsUninjected lesionsFirst doseIL-22Elevated IFNIL-6Immunomodulatory effectsBladder carcinoma
2013
A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients.
Amaravadi R, Senzer N, Martin L, Schilder R, LoRusso P, Papadopoulos K, Weng D, Graham M, Adjei A. A phase I study of birinapant (TL32711) combined with multiple chemotherapies evaluating tolerability and clinical activity for solid tumor patients. Journal Of Clinical Oncology 2013, 31: 2504-2504. DOI: 10.1200/jco.2013.31.15_suppl.2504.Peer-Reviewed Original ResearchCarboplatin/paclitaxelDose-limiting toxicityLiposomal doxorubicinMultiple chemotherapyDose escalationClinical benefitExcellent tolerabilityClinical activityClinical studiesRefractory solid tumorsPhase 1 studySolid tumor patientsFurther clinical studiesAnti-tumor synergyHighest dose levelNotable clinical activityApoptotic pathway activationG regimenStable diseaseStandard dosingProgressive diseasePartial responseBell's palsyTolerable combinationReversible toxicity
2006
Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors
Lorusso P, Heath E, Valdivieso M, Pilat M, Wozniak A, Gadgeel S, Shields A, Puchalski T, Ewesuedo R. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. Journal Of Clinical Oncology 2006, 24: 3034-3034. DOI: 10.1200/jco.2006.24.18_suppl.3034.Peer-Reviewed Original ResearchVascular endothelial growth factor receptorDose-limiting toxicityArm 1Chemotherapy regimensArm 2Arm 4Grade 3 hand-foot syndromeSolid tumorsGrade 4 neutropenic feverGrade 3 diarrheaGrade 3 fatigueGrade 3 hypertensionHand-foot syndromePhase I evaluationPre-treated patientsAdvanced solid tumorsPhase I trialEndothelial growth factor receptorSolid tumor patientsDuration of responseSelective inhibitorEfficacy/toxicityGrowth factor receptorIdentical chemotherapyNeutropenic fever